tbuckley/cabot-search huggingface dataset:
Expression of TLR4 and integrin β1 in breast cancer.
Authors: B. Petricevic, D. Vrbanec, J. Jakic Razumovic, Z. Dembic
Journal: Journal of Clinical Oncology (2010)

e21019 Background: Toll-like receptors (TLR) expressed on cells of immune system are essential for provoking the innate response and enhancing adaptive immunity against pathogens. Lately, TLRs were also detected on various tumor cells and their role in tumor pathogenesis was proven. Thus the stimulation of TLR4 receptors of colon cancer cells with lipopolysaccharide enhanced its invasivness and progression by upregulating the expression of integrin β1. Based on these results the aim of our study was to measure TLR4 and integrin β1 expression on breast cancer cells of tumor samples of our patients and compare it with the disease free period and survival. Methods: We analyzed the group of 124 patients with early breast cancer who were treated and followed from the year 2002 in the University Hospital Centre Zagreb, Department of Oncology; their average age was 57 years (30-81 years). The anaysis of TLR4 and integrin β1 on tumor cells was done using immunohistochemistry. Results: The patients were divided in two groups according to TLR4 expression. The group with positive TLR4 expression had shorter survival and disease free period, while the mortality was higher (survival: TLR4 neg. 38 months, TLR4 pos.: 33,5 m.; DSF: TLR4 neg.: 38 m., TLR4 pos.: 32,1 m., mortality: TLR4 neg.: 0%, TLR4 pos.: 5%). According to the expression of integrin β1 patients were divided into four groups: with no expression (0), as well as three grades of expression (I,II,III). The patients with no integrin β1 and those with low expression (I) on cancer cells had shorter DSF compared to those with higher expression (II, III). Mortality was higher with those patients having higher integrin β1 expression (in the nucleus and membrane). Conclusions: Expression of TLR4 on analysed breast cancer samples was connected with shorter survival and DSF, while higher integrin β1 expression correlated with the longer DSF. TLR4 Patient died Survival DSF β1 integrin 0 I II III β1 integrin 0 + I II + III No Yes Months Months Negative 9 0 38 38 DSF Months Months Months Months Mortality % % % 100 0 Nucleus 24 29,2 32,94 32,65 Nucleus 0 3,4 Positive 77 4 33,25 31,78 Cytoplasm 24 33,53 30,71 33,27 Cytoplasm 0 7,4 % 95,06 4,94 Membrane 31,91 29,75 39,17 34,4 Membrane 4,7 0 No significant financial relationships to disclose.
Rapid serum glucose normalization in insulinoma patients on everolimus due to its effects on tumor as well as normal tissues.
Authors: E. Siemerink, H. Fiebrich, A. H. Brouwers, G. Hospers, E. De Vries
Journal: Journal of Clinical Oncology (2010)

e14509 Background: mTOR inhibitor everolimus administered to 4 insulinoma patients showed rapid restoration of hypoglycaemia (Kulke et al. N Engl J Med 360:195-197, 2009). We wanted to identify the kinetics of everolimus-effects on controlling hypoglycemia and understand underlying mechanisms. Methods: Three consecutive patients with a metastasized symptomatic insulinoma were started on octreotide three times daily 100 μg subcutaneously. Because of persisting hypoglycemias, treatment with daily 10 mg everolimus orally was initiated. Serial plasma glucose levels and serum insulin levels were measured. CT scans were performed before and after 2 and 5 months of treatment. 18F-FDG-PET scans, to visualize glucose metabolism, were made before, and after 2 weeks, 5 weeks and 5 months of treatment. Standardized uptake values (SUVs) on PET were calculated to quantify tracer uptake. Results: All patients achieved control of hypoglycemia on everolimus within 14 days. Serum insulin levels were 2.5-6.3-fold elevated before start of treatment and declined 14-64% after 4 weeks compared to before treatment. CT scans showed stable disease at 2 months in all patients with progressive disease after 5 months in one. Before treatment 18F-FDG-PET scans showed high uptake in the tumor lesions, but also increased uptake in the muscles and the myocardium. Everolimus reduced tumor and muscle 18F-FDG uptake after 2 weeks by respectively 26 ± 14% and 19 ± 41% and after 5 months by 31 ± 13% and 27 ± 41%. Conclusions: Everolimus normalizes plasma glucose levels in metastatic insulinoma within 14 days which coincides with a lower glucose uptake in tumor and muscles and a decline in (pro)insulin levels. This effect on tumor as well as normal tissues of everolimus explains the rapid observed controlling of hypoglycemia. No significant financial relationships to disclose.
Iatrogenic common bile duct injuries: Increasing complexity in the laparoscopic era: A prospective cohort study
Authors: N.M. Hogan, D. Dorcaratto, A.M. Hogan, F. Nasirawan, P. McEntee, D. Maguire, J. Geoghegan, O. Traynor, D.C. Winter, E. Hoti
Journal: International Journal of Surgery (2016)
Improved Molecular Diagnosis of Aplastic Anemia/Bone Marrow Failure Syndromes Using a Novel Comprehensive Next Generation Sequencing Gene Panel
Authors: Majed Dasouki, Syed Osman Ahmed, Ali Alahmari, Amal Jabr, Moheeb Ali Alawwami, Naeem A. Chaudhri, AlMohareb Fahad, Said Y Mohamed, Walid Rasheed, Hazza A Alzahrani, Mahmoud Aljurf
Journal: Blood (2015)
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
Authors: Chezi Ganzel, Judith Manola, Dan Douer, Jacob M. Rowe, Hugo F. Fernandez, Elisabeth M. Paietta, Mark R. Litzow, Ju-Whei Lee, Selina M. Luger, Hillard M. Lazarus, Larry D. Cripe, Peter H. Wiernik, Martin S. Tallman
Journal: Journal of Clinical Oncology (2016)

Purpose Extramedullary disease (EMD) at diagnosis in patients with acute myeloid leukemia (AML) has been recognized for decades. Reported herein are results from a large study of patients with AML who were treated in consecutive ECOG-ACRIN Cancer Research Group frontline clinical trials in an attempt to define the incidence and clinical implications of EMD. Methods Patients with newly diagnosed AML, age 15 years and older, who were treated in 11 clinical trials, were studied to identify EMD, as defined by physical examination, laboratory findings, and imaging results. Results Of the 3,522 patients enrolled, 282 were excluded, including patients with acute promyelocytic leukemia, incorrect diagnosis, or no adequate assessment of EMD at baseline. The overall incidence of EMD was 23.7%. The sites involved were: lymph nodes (11.5%), spleen (7.3%), liver (5.3%), skin (4.5%), gingiva (4.4%), and CNS (1.1%). Most patients (65.3%) had only one site of EMD, 20.9% had two sites, 9.5% had three sites, and 3.4% had four sites. The median overall survival was 1.035 years. In univariable analysis, the presence of any EMD ( P = .005), skin involvement ( P = .002), spleen ( P < .001), and liver ( P < .001), but not CNS ( P = .34), nodal involvement ( P = .94), and gingival hypertrophy ( P = .24), was associated with a shorter overall survival. In contrast, in multivariable analysis, adjusted for known prognostic factors such as cytogenetic risk and WBC count, neither the presence of EMD nor the number of specific sites of EMD were independently prognostic. Conclusion This large study demonstrates that EMD at any site is common but is not an independent prognostic factor. Treatment decisions for patients with EMD should be made on the basis of recognized AML prognostic factors, irrespective of the presence of EMD.
Baseline and second round results from the population based Dutch-Belgian randomized lung cancer screening trial (NELSON)
Authors: R. V. van Klaveren, M. Oudkerk, W. Mali, E. Scholten, K. Nackaerts, E. Thunnissen, H. J. de Koning
Journal: Journal of Clinical Oncology (2008)

1508 Background: Early lung cancer detection with X-ray was unable to reduce lung cancer mortality. Low-dose spiral CT screening cohort studies have demonstrated that lung cancer can be detected at an early stage in a high percentage. Unknown is whether spiral CT screening will lead to a lung cancer mortality reduction and if lung cancer screening will be cost-effective. These questions will be addressed in the randomized Dutch-Belgian-Danish lung cancer screening trial (NELSON) of 20,000 participants. Methods: To identify high-risk subjects a health questionnaire was sent to 600,000 men and women aged 50–74 in seven Dutch public health districts and 14 municipalities in Belgium. Current and former smokers (quit < 10 years) who smoked at least 16 cigarettes a day for at least 26 years or at least 11 cigarettes a day for at least 31 years were invited. After receiving informed consent, participants were randomized between screen-arm and control-arm (usual care). CT scans are performed with 16-detector multi-slice Spiral CT scanners and Siemens Lungcare workstations and software for volumetric analyses in all 4 screening sites. The Lungcare radiological data are automatically uploaded in the NELSON Management System (NMS). Results and Conclusions: In the Netherlands and Belgium, 15,822 subjects have been randomized (1:1) and have undergone baseline and 2nd round sceening one year later. Of them, 83% was male and 17% female, 56% current smoker and 44% former smoker. The majority of current (n=1558) and former (n=1355) smokers had a smoking history of 30–39 PY. Of the former smokers, 62% had quit < 6 yrs and 36% between 6–10 yrs. In total 13,081 nodules have been detected at baseline. Of them, 66% were benign or < 50 mm3 and needed no further evaluation, 30% was indeterminate and 4% was larger than 500 mm3 and required further work-up and evaluation. Data on detection rates, disease stage volume doubling times and natural history of individual nodules after 2 years of follow-up will be presented at the meeting. No significant financial relationships to disclose.
Recurrent <i>TRIO</i> Fusion in Nontranslocation–Related Sarcomas
Authors: Lucile Delespaul, Tom Lesluyes, Gaëlle Pérot, Céline Brulard, Lydia Lartigue, Jessica Baud, Pauline Lagarde, Sophie Le Guellec, Agnès Neuville, Philippe Terrier, Dominique Vince-Ranchère, Susanne Schmidt, Anne Debant, Jean-Michel Coindre, Frédéric Chibon
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Despite various differences, nontranslocation-related sarcomas (e.g., comprising undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxofibrosarcoma) are unified by their complex genetics. Extensive analysis of the tumor genome using molecular cytogenetic approaches showed many chromosomal gains, losses, and translocations per cell. Genomic quantitative alterations and expression variations have been extensively studied by adapted high-throughput approaches, yet translocations still remained unscreened. We therefore analyzed 117 nontranslocation-related sarcomas by RNA sequencing to identify fusion genes. Experimental design: We performed RNA sequencing and applied a bioinformatics pipeline dedicated to the detection of fusion transcripts. RT-PCR and Sanger sequencing were then applied to validate predictions and to search for recurrence and specificity. Results: Among the 6,772 predicted fusion genes, 420 were in-frame. One recurrent rearrangement, consistently involving TRIO with various partners, was identified in 5.1% of cases. TRIO translocations are either intrachromosomal with TERT or interchromosomal with LINC01504 or ZNF558. Our results suggest that all translocations led to a truncated TRIO protein either directly or indirectly by alternative splicing. TRIO rearrangement is associated with a modified transcriptomic program to immunity/inflammation, proliferation and migration, and an increase in proliferation. Conclusions: TRIO fusions have been identified in four different sarcoma histotypes, likely meaning that they are not related to a primary oncogenic event but rather to a secondary one implicated in tumor progression. Moreover, they appear to be specific to nontranslocation-related sarcomas, as no such rearrangement was identified in sarcomas with simple genetics. More cases could lead to a significant association of these fusions to a specific clinical behavior. Clin Cancer Res; 23(3); 857–67. ©2016 AACR.
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
Authors: J F Novotny, J Cogswell, H Inzunza, C Harbison, C Horak, S Averbuch
Journal: Annals of Oncology (2016)

The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx assay may be used to determine tumor PD-L1 expression as a complementary and informative test.
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
Authors: Jason W D Hearn, Ghada AbuAli, Chad A Reichard, Chandana A Reddy, Cristina Magi-Galluzzi, Kai-Hsiung Chang, Rachel Carlson, Laureano Rangel, Kevin Reagan, Brian J Davis, R Jeffrey Karnes, Manish Kohli, Donald Tindall, Eric A Klein, Nima Sharifi
Journal: The Lancet Oncology (2016)
Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis
Authors: C. Huard, S.V. Gullà, D.V. Bennett, A.J. Coyle, R.A. Vleugels, S.A. Greenberg
Journal: British Journal of Dermatology (2016)

Dermatomyositis (DM) is an autoimmune disease primarily affecting skin and muscle. The purpose of this study was to determine whether an association exists between clinical skin disease activity as measured by the validated Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and type 1 interferon (IFN) pathway biomarkers in the blood of patients with DM. Forty‐two patients with DM and 25 healthy volunteers were prospectively enrolled. CDASI scores were obtained, and serum and blood RNA were isolated from all participants. Associations between CDASI activity and type 1 IFN‐inducible gene signature were assessed cross‐sectionally in all patient samples and longitudinally on 13 paired visits via transcriptional profiling analyses. By RNAseq analysis, type 1 IFN‐inducible genes were the most highly differentially regulated. A CDASI activity threshold of 12 was correlated with an elevated type 1 IFN gene signature and with serum IFN‐β, but not with IFN‐α protein. Expression analysis showed that all patients with mild disease activity had a low type 1 IFN gene signature, while 93% of patients with moderate‐to‐high disease activity had elevated gene signature. In longitudinal analysis, changes in CDASI activity showed nonsignificant trends with concordant directional changes in gene signature. A type 1 IFN pathway signature biomarker in blood is highly correlated with CDASI activity scores in DM, and may be a promising surrogate clinical trial end point. The correlation of serum IFN‐β, but not IFN‐α, with both a gene signature and CDASI suggests that IFN‐β drives disease activity in DM.
14-3-3η is a novel growth-promoting and angiogenic factor in hepatocellular carcinoma
Authors: Jian Shen, Fei Jiang, Ye Yang, Guangming Huang, Fuxing Pu, Qinqiang Liu, Lijun Chen, Liang Ju, Ming Lu, Fei Zhou, Chi Zhang, Xiagang Luo, Xiaojun Yang, Chengyu Jiao, Xiangcheng Li, Zhong Li, Yuan Li, Jianping Zhang
Journal: Journal of Hepatology (2016)
Autologous Stem Cell Transplantation For Acute Leukemias In Suzhou (China): Similar Outcome In CR1 Patients Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis
Authors: Jia Chen, Yin Lu, Myriam Labopin, De Pei Wu, Mohamad Mohty, Norbert Claude Gorin
Journal: Blood (2013)
How Does Caregiver Well-Being Relate to Perceived Quality of Care in Patients With Cancer? Exploring Associations and Pathways
Authors: Kristin Litzelman, Erin E. Kent, Michelle Mollica, Julia H. Rowland
Journal: Journal of Clinical Oncology (2016)

Purpose Perceived quality of care (QOC) is an increasingly important metric of care quality and can be affected by such factors among patients with cancer as quality of life and physician trust. This study sought to evaluate whether informal caregiver well-being was also associated with perceived QOC among patients with cancer and assessed potential pathways that link these factors. Methods This study used data from the Cancer Care Outcomes Research and Surveillance (CanCORS) consortium. Patients with lung and colorectal cancer enrolled in CanCORS (N = 689) nominated an informal caregiver to participate in a caregiving survey. Both groups self-reported sociodemographic, psychosocial, and caregiving characteristics; cancer characteristics were obtained from the CanCORS core data set. Multivariable logistic regression was used to assess the association between caregiver psychosocial factors and subsequent patient-perceived QOC, controlling for earlier patient-perceived QOC and covariates. Secondary analysis examined potential pathways that link these factors. Results Patients whose informal caregiver had higher levels of depressive symptoms were significantly more likely to report fair or poor QOC (odds ratio, 1.06; 95% CI, 1.01 to 1.13). When caregivers reported fair or poor self-rated health, patients were more than three times more likely to report fair or poor perceived QOC (odds ratio, 3.76; 95% CI, 1.76 to 9.55). Controlling for patient psychosocial factors and physician communication and coordination of medical care reduced the effect size and/or statistical significance of these relationships. Conclusion Informal caregivers are an important part of the care team and their well-being is associated with patient-perceived QOC. Engaging informal cancer caregivers as part of the care team and conducting ongoing risk stratification screening and intervention to optimize their health may improve patient-reported outcomes and QOC.
Molecular Pathways of Response to Recombinant Human Erythropoietin (rHuEpo) in Myelodysplastic patients Assayed with Macroarrays.
Authors: Cortelezzi Agostino, Colombo Gualtiero, Pellegrini Caterina, Silvestris Ilaria, Bosari Silvano, Lambertenghi Deliliers Giorgio, Fracchiolla S. Nicola
Journal: Blood (2004)
Health Research and the HIPAA Privacy Rule
Authors: Samuel J. Tilden
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A PHASE I TOXICITY, DOSE FINDING AND PRELIMINARY EFFICACY ASSESSMENT OF LIPOTEICHOIC ACID-T FOR PLEURODESIS IN MALIGNANT PLEURAL EFFUSION
Authors: N M Rahman, H E Davies, M Salzberg, E L Hedley, P Truogg, R Midgley, D Kerr, C Clelland, Davies Rjo.
Journal: Thorax (2008)
Clostridium difficile PCR ribotypes 001 and 176 – the common denominator of C. difficile infection epidemiology in the Czech Republic, 2014
Authors: Marcela Krutova, Jana Matejkova, Ed J Kuijper, Pavel Drevinek, Otakar Nyc
Journal: Eurosurveillance (2016)

In 2014, 18 hospitals in the Czech Republic participated in a survey of the incidence of Clostridium difficile infections (CDI) in the country. The mean CDI incidence was 6.1 (standard deviation (SD):7.2) cases per 10,000 patient bed-days and 37.8 cases (SD: 41.4) per 10,000 admissions. The mean CDI testing frequency was 39.5 tests (SD: 25.4) per 10,000 patient bed-days and 255.8 tests (SD: 164.0) per 10,000 admissions. A total of 774 C. difficile isolates were investigated, of which 225 (29%) belonged to PCR ribotype 176, and 184 isolates (24%) belonged to PCR ribotype 001. Multilocus variable-number tandem repeat analysis (MLVA) revealed 27 clonal complexes formed by 84% (190/225) of PCR ribotype 176 isolates, and 14 clonal complexes formed by 77% (141/184) of PCR ribotype 001 isolates. Clonal clusters of PCR ribotypes 176 and 001 were observed in 11 and 7 hospitals, respectively. Our data demonstrate the spread of two C. difficile PCR ribotypes within 18 hospitals in the Czech Republic, stressing the importance of standardising CDI testing protocols and implementing mandatory CDI surveillance in the country.
Temozolomide and irinotecan for relapsed glioma: Charing Cross Hospital experience
Authors: A. G. Young, P. J. Mulholland, A. D. Waldman, F. Roncaroli, K. S. O’Neill, S. J. Davidson, M. G. Glaser, C. S. Brock, E. S. Newlands
Journal: Journal of Clinical Oncology (2007)

12504 Background: Patients (pts) with relapsed glioma have poor prognosis with few treatment options. Methods: Retrospective analysis was made of toxicity and outcome in pts with relapsed glioma treated between 2001–06 with temozolomide (TMZ, 75mg/m2/day, D1–21) &amp; irinotecan (IRINO, 125mg/m2, D1, 8, 15), q35. Toxicity was graded using NCI-CTC version 2.0. Progression free survival (PFS) was calculated from start of TMZ/IRINO to relapse. Results: 24 pts (M:F, 15:9) were treated, comprising glioblastoma multiforme (GBM) (n=11); anaplastic astrocytoma (AA) (n=7); astrocytoma (n=4); oligoastrocytoma (n=2). Primary treatment following biopsy (n=12) or debulking surgery (n=12) was radiotherapy (RT) alone (n=12) or in combination with TMZ (n=12) (Stupp et al, 2005). At relapse, 10/24 pts received TMZ/IRINO as second-line therapy following TMZ+RT. 12/24 pts received third-line TMZ/IRINO, after TMZ alone (n=9), or TMZ/procarbazine (PCB) (n=2) or IRINO alone (n=1). 2/24 pts received fourth-line TMZ/IRINO, after TMZ then IRINO (n=1) &amp; after TMZ/PCB then IRINO (n=1). 19/21 pts took enzyme-inducing antiepileptic drugs (EIAED). EIAEDs can potentially reduce IRINO exposure. 218 chemotherapy cycles (median, 5; range 1–42+) were given. Grade (G) 3 or 4 hematological toxicities were leucopenia (G3, n=3, 1.4%), neutropenia (G3, n=3, 1.4%; G4, n=1, 0.5%), lymphopenia (G3, n=64, 29%). 5 pts (20.8%) had cotrimoxazole prophylaxis; 1 pt developed PCP on it. 1 pt developed G3 urogenital sepsis. There were no other G3 or G4 toxicities. 13 cycles were delayed due to G2 infection (5.9%). 3 pts had dose reductions.1 pt died from AML; in retrospect symptoms appear to pre-date treatment start. Overall median PFS was 6 months (mo) (range 1.5–39.75+ mo). Overall 2 yr PFS was 28% (95%CI: 10–47%). Median PFS was: GBM 2.5mo (range 1.5–27.25+ mo); AA 11.5 mo (range 2–33.5+ mo). Median 2yr PFS was: GBM 27% (95%CI: 1–53%); AA 14% (95%CI: 0–40%) Conclusions: TMZ/IRINO is well tolerated in heavily pre- treated pts &amp; warrants further evaluation. Long PFS was seen in pts with relapsed GBM &amp; AA. Importantly, re-challenge including TMZ can induce durable response. [Table: see text]
Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction
Authors: Avishay Grupper, Jose Nativi-Nicolau, Joseph J. Maleszewski, Jennifer R. Geske, Walter K. Kremers, Brooks S. Edwards, Sudhir S. Kushwaha, Naveen L. Pereira
Journal: JACC Heart Failure (2016)
Priming Regiments Based on Idarubicin, or Aclacinomycin or Pirarubicin Combining with Cytarabine and Granulocyte-Colony Stimulating Factor for Reinduction of Refractory/Relapsed Acute Lymphoblastic Leukemia
Authors: Yu Zhu, Guangsheng He, Kourong Miao, Huayuan Zhu, Weyi Shen, Wang Shuai
Journal: Blood (2015)